Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
$5.08
-$0.15(-2.50%)
At close: 4:00 PM EST
$5.08
-$0.15(-2.50%)
Day’s Range― - ―
52-Week Range$3.93 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)1.05M
Market Cap
$275.29M
Enterprise Value$216.18M
Total Cash (Recent Filing)$207.46M
Total Debt (Recent Filing)$24.11M
Price to Earnings (P/E)4.4
Beta0.94
Next Earnings
Mar 23, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding54,191,360
10 Day Avg. Volume1,258,720
30 Day Avg. Volume1,050,140
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.19
Price to Sales (P/S)0.00
P/FCF Ratio-3.91
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue540.44
Enterprise Value/Gross Profit-224.25
Enterprise Value/Ebitda2.41
Forecast
1Y Price Target
$25.17Price Target Upside395.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$111.10M
Bulls Say, Bears Say
Bulls Say
Commercial Rollout And Patient DemandActivation of multiple qualified treatment centers and the treatment of the first commercial patient demonstrate rising patient demand and provide a scalable launch pathway that can drive sustained commercial uptake and improved cash flow.
Regulatory ApprovalRegulatory resubmission for UX111 includes substantial long-term clinical and biomarker evidence with FDA acknowledgement of robust neurodevelopmental outcomes, and approval would establish the first therapy for Sanfilippo type A while creating meaningful upside to analyst valuations.
Reimbursement And CodingPermanent CMS coding together with published coverage policies from major commercial payers should streamline insurance processing for ZEVASKYN and reduce access barriers, supporting faster patient adoption.
Bears Say
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.93 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $275.29M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Mar 23, 2026 which is in 45 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.282 by $0.182.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 54,191,360 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.282. Following the earnings report the stock price went up 18.465%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.17 (395.47% Upside)
$25.17 (395.47% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 841.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 48.7%
Last 30 Days ▲ 48.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.18%
12-Months-Change
Fundamentals
Return on Equity
75.90%
Trailing 12-Months
Asset Growth
91.63%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook for Abeona Therapeutics, with strong advancements in the commercial launch of ZivaSkin, expansion of treatment centers, and favorable market access. However, there were notable challenges, including delays in patient treatment and increased SG&A expenses. The company's financial position remains strong, and its pipeline shows promising advancements.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$25.17
▲(395.47% Upside)
Technical Analysis
Ownership Overview
5.28% Insiders
6.72% Mutual Funds
40.75% Other Institutional Investors
38.12% Public Companies and
Individual Investors